Active	Status	Sponsor type	Region	Phase	Filter
21 Active 7 Inactive 28 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oral, Elif A
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy	Active, not recruiting	4	10	US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalized Lipodystrophy	10/24	04/25
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy	Recruiting	3	15	US	Metreleptin	Amryt Pharma	Familial Partial Lipodystrophy	03/28	03/28
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL	Recruiting	3	65	Europe, Canada, US, RoW	metreleptin, Placebo	Amryt Pharma	Partial Lipodystrophy	06/25	01/26
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)	Active, not recruiting	2	4	US	Metreleptin	University of Michigan, Amryt Pharma	Lipomatosis, Multiple Symmetrical	04/24	04/25
LEAP, NCT05088460 / 2021-000138-33: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)	Terminated	2	20	Europe, US, RoW	REGN4461, mibavademab, Matching Placebo	Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.	Familial Partial Lipodystrophy, Metabolic Abnormalities	12/23	04/24
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes	Suspended	N/A	320	Europe, US	Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)	Fractyl Health Inc.	Type 2 Diabetes	06/25	01/26
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry	Recruiting	N/A	100	Europe, US	Metreleptin	Aegerion Pharmaceuticals, Inc.	Generalised Lipodystrophy, Partial Lipodystrophy	10/31	10/31
Czerr, Jennifer
ALPESTRIA-1, NCT06425055: Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1	Active, not recruiting	2	20	Europe, US	Vonafexor, EYP001a	Enyo Pharma	Alport Syndrome	07/25	10/25
Neidert, Adam H
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes	Suspended	N/A	320	Europe, US	Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)	Fractyl Health Inc.	Type 2 Diabetes	06/25	01/26
Doshi, Mona D
SAFE KIDNEY II, NCT05769582: Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients	Recruiting	2/3	180	US	Anti-BK polyomavirus (AntiBKV)	Memo Therapeutics AG	BK Viremia; BKV DNAemia	11/24	11/24